BRPI0711311A2 - implante intraocular de agente vasoativo - Google Patents

implante intraocular de agente vasoativo Download PDF

Info

Publication number
BRPI0711311A2
BRPI0711311A2 BRPI0711311-0A BRPI0711311A BRPI0711311A2 BR PI0711311 A2 BRPI0711311 A2 BR PI0711311A2 BR PI0711311 A BRPI0711311 A BR PI0711311A BR PI0711311 A2 BRPI0711311 A2 BR PI0711311A2
Authority
BR
Brazil
Prior art keywords
implant
eye
vasodilator
intraocular
vasoactive
Prior art date
Application number
BRPI0711311-0A
Other languages
English (en)
Portuguese (pt)
Inventor
John E Donello
Rong Yang
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0711311A2 publication Critical patent/BRPI0711311A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
BRPI0711311-0A 2006-05-04 2007-05-01 implante intraocular de agente vasoativo BRPI0711311A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/417,420 US20070260203A1 (en) 2006-05-04 2006-05-04 Vasoactive agent intraocular implant
US11/417,420 2006-05-04
PCT/US2007/067883 WO2007130945A1 (en) 2006-05-04 2007-05-01 A sustained-release intraocular implant comprising a vasoactive agent

Publications (1)

Publication Number Publication Date
BRPI0711311A2 true BRPI0711311A2 (pt) 2011-12-06

Family

ID=38508941

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711311-0A BRPI0711311A2 (pt) 2006-05-04 2007-05-01 implante intraocular de agente vasoativo

Country Status (8)

Country Link
US (1) US20070260203A1 (https=)
EP (1) EP2026764B1 (https=)
JP (2) JP2009535422A (https=)
AU (1) AU2007248143B2 (https=)
BR (1) BRPI0711311A2 (https=)
CA (1) CA2651300C (https=)
DK (1) DK2026764T3 (https=)
WO (1) WO2007130945A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU2002236495B2 (en) 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US9849027B2 (en) 2007-11-08 2017-12-26 Alimera Sciences, Inc. Ocular implantation device
DE102008040786A1 (de) * 2008-07-28 2010-02-04 Biotronik Vi Patent Ag Biokorrodierbares Implantat mit einer Beschichtung enthaltend eine wirkstofftragende Polymermatrix
US20100204325A1 (en) * 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CA3186189A1 (en) 2009-05-18 2010-11-25 Dose Medical Corporation Drug eluting ocular implant
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
CA2798084A1 (en) 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US20120276186A1 (en) * 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US8883189B2 (en) 2011-09-27 2014-11-11 The Regents Of The University Of Colorado, A Body Corporate Intraocular encapsulation of oxygenic bacteria
CN109602691A (zh) * 2013-02-15 2019-04-12 阿勒根公司 持续药物递送植入物
EP3677229A1 (en) 2014-05-29 2020-07-08 Glaukos Corporation Implants with controlled drug delivery features
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP3442479B1 (en) 2016-04-20 2026-03-04 Glaukos Corporation Bioresorbable ocular drug delivery device
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
EP3893918B1 (en) * 2018-12-10 2024-09-25 Rigshospitalet Vasodilators for use in the treatment of a retinal ischemic disorder
GB2601922B (en) 2019-06-27 2024-04-24 Layerbio Inc Ocular device drub delivery systems
WO2021087399A1 (en) 2019-10-30 2021-05-06 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
US12226452B2 (en) * 2020-03-04 2025-02-18 The Schepens Eye Research Institute, Inc. Polyhedrin-based slow release growth factor system for neuroprotection of retinal ganglion cell neurons
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
CA3218251A1 (en) 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
AU2022264438A1 (en) * 2021-04-30 2023-11-23 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) * 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
CA2300154C (en) * 1997-08-11 2008-07-08 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2002236495B2 (en) * 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
AP1893A (en) * 2000-12-01 2008-09-23 Osi Pharm Inc Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US20050203542A1 (en) * 2002-09-18 2005-09-15 Allergan, Inc. Apparatus for delivery of ocular implants with reduced incidence of ocular adverse events
US7468065B2 (en) * 2002-09-18 2008-12-23 Allergan, Inc. Apparatus for delivery of ocular implants
US6899717B2 (en) * 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8512738B2 (en) * 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
BRPI0516308A2 (pt) * 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
CA2615360A1 (en) * 2005-07-15 2007-01-25 Chakshu Research Inc. Formulation and method for administration of ophthalmologically active agents

Also Published As

Publication number Publication date
EP2026764B1 (en) 2017-07-12
AU2007248143A1 (en) 2007-11-15
DK2026764T3 (en) 2017-10-23
US20070260203A1 (en) 2007-11-08
CA2651300C (en) 2015-09-15
WO2007130945A1 (en) 2007-11-15
AU2007248143B2 (en) 2012-11-08
JP2009535422A (ja) 2009-10-01
JP2014014694A (ja) 2014-01-30
EP2026764A1 (en) 2009-02-25
CA2651300A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
AU2007248143B2 (en) A sustained-release intraocular implant comprising a vasoactive agent
US20210161809A1 (en) Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
ES2658175T3 (es) Implantes intracamerales de agentes terapéuticos de liberación sostenida
JP5696121B2 (ja) α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント
JP5826872B2 (ja) 眼内使用のための環状脂質インプラントの製造法
AU2007223057B2 (en) Ocular therapy using sirtuin-activating agents
US8409607B2 (en) Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8529927B2 (en) Alpha-2 agonist polymeric drug delivery systems
BRPI0721055A2 (pt) Sistemas de liberação de fármacos intraoculares
JP2013126997A (ja) β−アドレナリン受容体拮抗薬を含む持続放出眼内インプラント
BRPI0608978A2 (pt) terapia ocular usando agonistas de receptor alfa-2 adrenérgico possuindo taxas de depuração anterior realçadas
AU2016231616A1 (en) Intraocular sustained release drug delivery systems and methods for treating ocular conditions
BRPI0915981A2 (pt) método para tratar a degeneração macular atrófica relacionada à idade
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
AU2014200076A1 (en) Ocular therapy using sirtuin-activating agents

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 3A, 4A E 5A ANUIDADES.